BeiGene

Company snapshot

Effective March 17, 2025, The U.S. subsidiary of BeiGene, Ltd. has changed its name to BeOne Medicines USA, Inc. This change comes ahead of our anticipated global rebranding to BeOne Medicines Ltd. and redomiciliation to Switzerland, pending shareholder approval. The new name reflects our commitment to develop innovative medicines and partner with the global community to help as many patients with

• 14 active pipeline program(s) linked via ClinicalTrials.gov.
• 25 US patent(s) indexed to this assignee profile.
• 14 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for BeiGene. Not investment advice.

• approval Jun 6, 2026

  Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?

• Peer + 0 momentum

  Daiichi Sankyo US

  TA overlap score 31.6

• Peer + 0 momentum

  MEREO BIOPHARMA GROUP

  TA overlap score 29.4

• Peer + 0 momentum

  RIGEL PHARMACEUTICALS

  TA overlap score 27.2

• Peer + 0 momentum

  Genmab

  TA overlap score 25.8

• Peer + 0 momentum

  Sichuan Baili Pharmaceutical

  TA overlap score 20.8

Recent activity

Latest pipeline, patent, and corporate events for BeiGene.

1. Jun 8, 2026 Clinical update

   BGB-A317-A3055-101 — Phase 1

2. Jun 8, 2026 Clinical update

   BGB-A317-A1217-302 — Phase 3

3. Jun 8, 2026 Clinical update

   BGB-21447-101 — Phase 1

4. Jun 8, 2026 Clinical update

   Pamiparib capsule — Phase 3

5. Jun 8, 2026 Clinical update

   OBINUTUZUMAB, Zanubrutinib — Phase 2

View all clinical trial activity →

• What is BeiGene?

  BeiGene is a pharma organization headquartered in Camana Bay, KY. Primary therapeutic focus areas include Advanced or metastatic solid tumors, Waldenström's Macroglobulinemia, Covid19, Ovarian Cancer, Carcinoma, Hepatocellular. NovaPharmaNews links 14 clinical program(s), 0 drug

• Is BeiGene publicly traded?

  BeiGene appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does BeiGene develop or market?

  We link 19 drug profile(s) where BeiGene is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/beigene-ireland-ltd#company-drugs.

• What are the latest developments for BeiGene?

  In the last 12 months our linked public records show 14 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does BeiGene focus on?

  BeiGene focuses on Advanced or metastatic solid tumors, Waldenström's Macroglobulinemia, Covid19 based on our analysis of their pipeline programs and drug development activities.